Helmholtz Gemeinschaft


CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells

Item Type:Article
Title:CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells
Creators Name:Lindencrona, J.A. and Preiss, S. and Kammertoens, T. and Schueler, T. and Piechocki, M. and Wei, W.Z. and Seliger, B. and Blankenstein, T. and Kiessling, R.
Abstract:HER-2/neu (HER-2) is a cell surface proto-oncogene that is often overexpressed in carcinomas. Passive administration of anti-HER-2 antibodies in breast cancer patients has achieved promising results, but less is known about the role of antibodies in active immunization. We asked whether B cells/antibodies are needed for tumor immunity induced by plasmid (HER-2 and GM-CSF) immunization. HER-2 specific tumor immunity relied completely on both CD4+ and CD8+ T cells. IFN-γ, and to a lesser extent IL-4, seemed to be crucial cytokines during tumor rejection. Protection was associated with production of anti-HER-2 IgG antibodies in B cell competent mice. After immunization, however, B cell-deficient mice rejected HER-2-expressing tumors as efficiently as control littermates. We conclude that T cells are the main effector cells in DNA vaccine induced immunity against HER-2 and that anti HER-2 antibodies are not necessary to elicit a protective anti tumor immune response in this model.
Keywords:Anti-Tumor Immunity, CTL, DNA Vaccine, HER-2
Source:International Journal of Cancer
Publisher:Wiley (U.S.A.)
Page Range:259-264
Date:1 January 2004
Official Publication:https://doi.org/10.1002/ijc.11654
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library